BRIEF-Brooklyn Immunotherapeutics Inc- On Sept 9, Co Entered Into A Master Services Agreement With Factor Bioscience Inc.

Reuters2022-09-16

Sept 15 (Reuters) - Brooklyn Immunotherapeutics Inc :

* BROOKLYN IMMUNOTHERAPEUTICS INC- ON SEPT 9,CO ENTERED INTO A MASTER SERVICES AGREEMENT WITH FACTOR BIOSCIENCE INC.,

* BROOKLYN IMMUNOTHERAPEUTICS- UNDER MSA, FACTOR HAS AGREED TO PROVIDE CO WITH MRNA CELL ENGINEERING RESEARCH SUPPORT SERVICES

* BROOKLYN IMMUNOTHERAPEUTICS INC- COMPANY HAS AGREED TO PAY FACTOR AN INITIAL FEE OF $5 MILLION

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2267363210?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-09-16 04:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2267363210","market":"us","top_or_hot":-1,"title":"BRIEF-Brooklyn Immunotherapeutics Inc- On Sept 9, Co Entered Into A Master Services Agreement With Factor Bioscience Inc.","media":"Reuters","content":"<html><body><p>Sept 15 (Reuters) - Brooklyn Immunotherapeutics Inc   :</p><p>   * BROOKLYN IMMUNOTHERAPEUTICS INC- ON SEPT 9,CO ENTERED INTO A MASTER SERVICES AGREEMENT WITH FACTOR BIOSCIENCE INC.,</p><p>   * BROOKLYN IMMUNOTHERAPEUTICS- UNDER MSA, FACTOR HAS AGREED TO PROVIDE CO WITH MRNA CELL ENGINEERING RESEARCH SUPPORT SERVICES</p><p>   * BROOKLYN IMMUNOTHERAPEUTICS INC- COMPANY HAS AGREED TO PAY FACTOR AN INITIAL FEE OF $5 MILLION</p><p>Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Brooklyn Immunotherapeutics Inc- On Sept 9, Co Entered Into A Master Services Agreement With Factor Bioscience Inc.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Brooklyn Immunotherapeutics Inc- On Sept 9, Co Entered Into A Master Services Agreement With Factor Bioscience Inc.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-16 04:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 15 (Reuters) - Brooklyn Immunotherapeutics Inc   :   * BROOKLYN IMMUNOTHERAPEUTICS INC- ON SEPT 9,CO ENTERED INTO A MASTER SERVICES AGREEMENT WITH FACTOR BIOSCIENCE INC.,   * BROOKLYN ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APR","symbol_name":"Apria, Inc.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2267363210","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2267363210","pubTimestamp":1663274699,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 15 (Reuters) - Brooklyn Immunotherapeutics Inc   :   * BROOKLYN IMMUNOTHERAPEUTICS INC- ON SEPT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APR":"Apria, Inc.","CRCT":"Cricut, Inc.","SANA":"Sana Biotechnology, Inc.","BK4196":"保健护理服务","ONTF":"ON24, Inc.","BK4139":"生物科技","BOLT":"Bolt Biotherapeutics, Inc.","BK4191":"家用电器","BK4082":"医疗保健设备","TERN":"Terns Pharmaceuticals, Inc.","BK4023":"应用软件","CGEM":"Cullinan Therapeutics","LABP":"Landos Biopharma, Inc.","BK4007":"制药","BK4539":"次新股","LHDX":"Lucira Health, Inc."},"translate_title":"布鲁克林免疫治疗公司9月9日与因子生物科学公司达成了一项主服务协议。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOLT":1,"TERN":1,"SANA":1,"ONTF":1,"LHDX":1,"LABP":1,"CRCT":1,"CGEM":1,"APR":1,"BTX":0.9},"content_text":"Sept 15 (Reuters) - Brooklyn Immunotherapeutics Inc   :   * BROOKLYN IMMUNOTHERAPEUTICS INC- ON SEPT 9,CO ENTERED INTO A MASTER SERVICES AGREEMENT WITH FACTOR BIOSCIENCE INC.,   * BROOKLYN IMMUNOTHERAPEUTICS- UNDER MSA, FACTOR HAS AGREED TO PROVIDE CO WITH MRNA CELL ENGINEERING RESEARCH SUPPORT SERVICES   * BROOKLYN IMMUNOTHERAPEUTICS INC- COMPANY HAS AGREED TO PAY FACTOR AN INITIAL FEE OF $5 MILLIONFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2267363210"}